The Stago group announced today that it has completed the acquisition of HemoSonics LLC, a company specialized in the development of innovative Point-of-Care testing solutions based in Charlottesville, VA, with facilities in Durham, NC (USA).

With the acquisition of the patented SEER technology (Sonic Estimation of Elasticity via Resonance) and its associated QuantraTM Hemostasis Analyzer, Stago demonstrates its willingness to develop a Point-of-Care offering to complete its leadership in Haemostasis testing and beyond.

This transaction provides Stago with expanded opportunities for future growth and is an important part of the company’s on-going efforts to diversify its portfolio of medical devices in an ever-changing healthcare environment.

“This significant step makes us very proud to contribute to the management of healthcare costs and to the improvement of patients outcomes worldwide,” says Lionel Viret, Chairman of the Board.

“Stago brings exceptional expertise in the field of Thrombosis and Hemostasis that will greatly advance our efforts to rapidly and effectively deliver a new standard of care for the management of bleeding in the critical care setting,” says Timothy Fischer, President and Chief Executing Officer of HemoSonics.

Ferghana Partners acted as exclusive financial advisor to HemoSonics for this transaction.

About Stago

Leading player in the In-Vitro Diagnostics industry dedicated to the exploration of Thrombosis and Haemostasis, Stago develops and markets automated systems for blood analysis in coagulation. Created in 1945, Stago is fully dedicated to Haemostasis since 1962. Privately-owned and independent, Stago is headquartered in Asnières, France, with R&D, manufacturing and logistics activities mainly in Europe. Its products are available in 115 countries through a network of 20 subsidiaries and 94 distributors. Stago Group’s headcount is currently 2,400 employees worldwide. For more information, visit www.stago.com.

About HemoSonics

HemoSonics is a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding to improve outcomes and reduce healthcare costs by enabling more targeted transfusion of blood products. The QuantraTM Hemostasis Analyzer is designed to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely information on coagulation status at the point of care. HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. For more information, visit www.hemosonics.com.